Mylan/Biocon’s Insulin Glargine Would Get A Respite Under US Budget Legislation
Executive Summary
Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.
You may also be interested in...
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At AAM
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At Generics Group
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline
US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.